Drugs / SQ109
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01358162 | Nov 2010 → Feb 2011 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00866190 | Apr → Nov 2009 | multidrug-resistant tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01585636 | Sep 2006 → Feb 2007 | tuberculosis | Sequella, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01874314 | ? → Dec 2015 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01785186 | Apr 2013 → Sep 2014 | pulmonary tuberculosis | Michael Hoelscher | Completed | No outcome recorded |
| Phase 2 | NCT01252108 | Mar 2012 → Aug 2015 | Helicobacter pylori infectious disease | Sequella, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT01218217 | Nov 2010 → Sep 2011 | pulmonary tuberculosis | Michael Hoelscher | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SQ109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01358162 ↗ |
| Known as | NSC-722041 | ChEMBL registry synonym — accepted as the source's own label CHEMBL561057 ↗ |
| Modality | Small molecule | “SQ109 is a new, small molecule antibiotic with characteristics that make it particularly attractive to evaluate against H. pylori.” NCT01252108 ↗ |
| Route | Oral | “oral SQ109” NCT00866190 ↗ |